Sun Yat-sen University: Carcinoma, Hepatocellular trials

The registry lists 175 Carcinoma, Hepatocellular studies with Sun Yat-sen University as lead sponsor. 52 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 55Phase 3 54Phase 4 18No phase 50(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dapagliflozin Add-on in Unresectable HCC With Metabolic SyndromeNot yet recruitingNCT07729592Phase 2
• SBRT Versus Surgical Resection for Small HCCRecruitingNCT07381660Phase 3
• Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular CarcinomaRecruitingNCT07324824Phase 2
• TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular CarcinomaNot yet recruitingNCT07253220Not applicable
• Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & BevacizumabRecruitingNCT07192185Phase 2
• TACE Combined Surgery for the Resectable Huge HCCRecruitingNCT06898398
• Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular CarcinomaRecruitingNCT06788353
• TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular CarcinomaRecruitingNCT06740370Not applicable
• SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.Not yet recruitingNCT06739317Phase 2/3
• HAIC Compared With TACE in Huge Hepatocellular CarcinomaRecruitingNCT06641713
• Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular CarcinomaRecruitingNCT06624098Not applicable
• TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTTRecruitingNCT06622031Not applicable
• Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCCRecruitingNCT06609876Not applicable
• dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular CarcinomaRecruitingNCT06609863Not applicable
• The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular CarcinomaRecruitingNCT06609850Not applicable
• Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic TreatmentNot yet recruitingNCT06592612Phase 2
• Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular CarcinomaRecruitingNCT06550921Not applicable
• HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II StudyNot yet recruitingNCT06482008Phase 2
• Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCCRecruitingNCT06467799Phase 2
• Fruquintinib After ICIs Treatment in Unresectable Hepatocellular CarcinomaRecruitingNCT06446154Phase 2
• HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular CarcinomaRecruitingNCT06333561
• Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)RecruitingNCT06313190Phase 2
• Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary MetastasesRecruitingNCT06265350Not applicable
• FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind TrialRecruitingNCT06201065Phase 3
• A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular CarcinomaNot yet recruitingNCT06143579Phase 2
• Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)RecruitingNCT06090656Phase 2
• bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaRecruitingNCT06070636Not applicable
• bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCRecruitingNCT06061276Not applicable
• Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCRecruitingNCT06041477Phase 3
• Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical TrialRecruitingNCT06031285Phase 2
• HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialRecruitingNCT05886465Phase 2
• TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven CriteriaNot yet recruitingNCT05883176Phase 2
• HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCCRecruitingNCT05866172Phase 3
• Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical TrialRecruitingNCT05751343Phase 2
• A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic AgentsRecruitingNCT05718492Not applicable
• SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)Not yet recruitingNCT05718232Phase 3
• Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05609695
• Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular CarcinomaRecruitingNCT05573282
• HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority StudyRecruitingNCT05476432Phase 3
• Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular CarcinomaRecruitingNCT05444478Not applicable
• A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationRecruitingNCT05313282Phase 3
• Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCCRecruitingNCT05002452
• Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)RecruitingNCT04777942Not applicable
• Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational StudyRecruitingNCT04680598
• Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCCRecruitingNCT04615143Phase 2
• SBRT Versus Ablation for Perivascular Hepatocellular CarcinomaRecruitingNCT04434989Not applicable
• Neo-TACE-HAIC for BCLC B Stage HCCRecruitingNCT04424043Not applicable
• A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationRecruitingNCT04191889Phase 2
• HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized TrialRecruitingNCT04135690Phase 2
• Randomized Study of Adjuvant Radiotherapy After Curative Resection of HCC With Narrow Margin (RAISE)RecruitingNCT03732105Not applicable
• The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.RecruitingNCT03368651Phase 3
• Laparoscopic Surgery VS RFA for Recurrent HCCNot yet recruitingNCT02785380Phase 4
• Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular CarcinomaCompletedNCT04945720Phase 2Results posted
• Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative TrialActive, not recruitingNCT07380633Phase 2
• The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective StudyCompletedNCT07272265Not applicable
• AI Multitask Model for HCC TreatmentCompletedNCT07157085
• A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular CarcinomaActive, not recruitingNCT07138885Phase 2
• Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular CarcinomaActive, not recruitingNCT06524466Phase 2
• Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCCCompletedNCT06435013
• Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular CarcinomaCompletedNCT06199297
• Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular CarcinomaActive, not recruitingNCT05889949
• Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving ImmunotherapyStatus unknownNCT05620004Phase 1/2
• Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTTWithdrawnNCT05592197Not applicable
• AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)Status unknownNCT05578430Phase 2
• TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Phase 2
• Watch and Wait and Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular CarcinomaCompletedNCT05349331Phase 2
• Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular CarcinomaStatus unknownNCT05231382Phase 3
• TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Phase 3
• A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)Status unknownNCT05214339Phase 2
• Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized TrialActive, not recruitingNCT05198609Phase 3
• The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective StudyCompletedNCT05121571Not applicable
• Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular CarcinomaActive, not recruitingNCT05010434Phase 2
• The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04961918Phase 2
• PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814043Phase 2
• Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical TrialStatus unknownNCT04814030Phase 2
• TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical StudyStatus unknownNCT04796025Phase 2
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
• CT Perfusion Parameters Predict Vascular Pattern in Hepatocellular CarcinomaStatus unknownNCT04715321
• Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 TrialStatus unknownNCT04687163Phase 3
• HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority TrialStatus unknownNCT04667351Phase 3
• Ablation Combined With PD-1 in HCC: Phase II StudyStatus unknownNCT04652440Phase 1/2
• Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular CarcinomaCompletedNCT04627012
• HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
• A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative ResectionStatus unknownNCT04392700Phase 3
• Neo-TACE-HAIC for PVTT-HCCStatus unknownNCT04181931Not applicable
• Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2
• Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTTStatus unknownNCT04169399Phase 2
• Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCCStatus unknownNCT04143191Phase 3
• TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular CarcinomaCompletedNCT04103398Phase 3
• To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic EffectStatus unknownNCT04101747
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04053985Phase 3
• The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT04053972Phase 3
• RFA Versus SBRT for Recurrent Small HCCCompletedNCT04047173Phase 3
• Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver ResectionSuspendedNCT03990974Phase 3
• Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCCCompletedNCT03939975Phase 2
• Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2
• TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCCStatus unknownNCT03905967Phase 3
• RFA vs. SBRT for Small HCCStatus unknownNCT03898921Phase 3
• HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCCActive, not recruitingNCT03869034Phase 2
• The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03851939Phase 2